PGT-A Testing: Is It Worth $5,000?

Published May 21, 2026 · ConceiveGuide Editorial Team

Preimplantation genetic testing for aneuploidy (PGT-A) is one of the most debated add-ons in modern IVF. At $3,000 to $6,000 per cycle, it promises to identify chromosomally normal embryos before transfer — potentially reducing miscarriage risk and shortening time to pregnancy. But is it right for everyone?

What PGT-A Actually Tests

PGT-A screens embryos for the correct number of chromosomes (46 in a healthy embryo). Aneuploidy — having too many or too few chromosomes — is the leading cause of IVF failure, early miscarriage, and conditions like Down syndrome (trisomy 21).

The test involves removing 5-10 cells from the trophectoderm (the outer layer that becomes the placenta) at the blastocyst stage, typically day 5 or 6. These cells are sent to a genetics laboratory for analysis, and results return in 1-2 weeks.

Key distinction: PGT-A screens for chromosome count. PGT-M tests for specific inherited genetic diseases (like cystic fibrosis). PGT-SR screens for structural chromosomal rearrangements. They are different tests with different indications.

The Real Cost Breakdown

ComponentCost RangeNotes
Embryo biopsy (clinic fee)$1,500–$2,500Per cycle, regardless of embryo count
Genetic lab analysis$1,500–$3,500Often per embryo or tiered pricing
Embryo freezing$1,000–$1,500Required — results take 1-2 weeks
Frozen embryo transfer$3,000–$5,000Separate cycle for transfer
Total added cost$4,000–$6,500Above base IVF cycle

Some clinics bundle PGT-A into package pricing. Insurance coverage is rare but expanding — check if your plan covers "genetic testing" or "chromosomal screening" separately from IVF itself.

Who Benefits Most

ASRM's 2024 committee opinion acknowledges PGT-A can improve per-transfer success rates but notes it has not been definitively shown to improve cumulative live birth rates in all patient populations. The evidence is strongest for:

The Controversy

PGT-A is not without legitimate criticism:

Mosaicism: Some embryos labeled "abnormal" are actually mosaic — containing a mix of normal and abnormal cells. A percentage of mosaic embryos can self-correct during development and result in healthy babies. Discarding them means potentially losing viable embryos.

Biopsy risk: While generally considered safe, trophectoderm biopsy is an invasive procedure. Some studies suggest a small (1-2%) reduction in implantation potential from the biopsy itself.

False results: No genetic test is 100% accurate. False positives (normal embryos called abnormal) and false negatives (abnormal embryos called normal) both occur at low rates.

The core debate: PGT-A clearly improves per-transfer success rates by avoiding transferring aneuploid embryos. But if you would have eventually transferred those embryos anyway and discovered they failed, is a positive pregnancy test one month sooner worth $5,000? For many patients, yes. For others with limited embryos, discarding a potentially mosaic embryo that could have self-corrected is a real loss.

Questions to Ask Before Testing

The Bottom Line

PGT-A is a powerful tool when used in the right clinical context. It is most valuable for patients over 37, those with recurrent loss, or anyone who wants to minimize the emotional and physical toll of transferring embryos unlikely to succeed. It is less clearly beneficial for younger patients with many embryos who would reach a successful transfer regardless. Discuss your specific situation with your RE before deciding.

Related Reading

Explore More Resources

Track Your Cycle

OPK comparisons, BBT charts, and timing guides for every cycle type.

FertileStart →

Optimize Your Body

Evidence-based supplements, nutrition plans, and lifestyle changes for fertility.

LifeFertile →

The Full Picture

Your central hub for fertility news, research updates, and getting started.

HowToHaveABaby →
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified reproductive endocrinologist or healthcare provider for diagnosis and treatment decisions. Individual outcomes vary based on medical history, age, and other factors.